A new type of medicine for one of the most common type of advanced breast cancer is now available on NHS in England.

Some 3,000 women in a year may benefit from Capivusterb after a clinical testing, shown that it can slow down the progression of the disease, and a quarter may reduce tumors in people.

The drug has been given green lights for NHS funding by England’s Drug Assessment Body.

It is one of the alternatives that have spread cancer and now it is not good, but a cancer charity said that breast cancer drugs should be approved more rapidly.

Breast cancer is the most common cancer in the UK, with one in seven women affected during their lifetime and survives for 10 years or more after diagnosis.

If cancer returns to other parts of the body and spreads, treatment aims to control it, reduce symptoms and improve the quality of life.

Possible treatments include chemotherapy, radiotherapy, and drugs that help prevent cancer from growing – either by blocking hormones, promoting the body’s immune system or targeting from increasing cancer cells.

This new drug is Capivasertib is a targeted therapy. It works in a new way, blocking the activity of a protein molecule that is called AKT that increases the development of cancer.

Scientists started working on the development of medicine 20 years ago and say that it is the most effective cancer medicine that they have seen for advanced cancer.

“This offers a very effective option that can work for a long time – several months, and in some people may have years,” said Professor Nick Turner, lead researcher and professor at the Institute of Cancer Research and Royal Marsden at the Institute of Cancer Research and Royal Marsden.

In tests, in 708 women, When combined with hormone therapyThe drug doubled the increase in cancer from 3.6 months to 7.3 months. It also shrinks tumors in 23% of patients.

“It can delay chemotherapy significantly that is afraid of many women due to side effects,” said Pro Turner.

“Advanced breast cancer is highly treatable and we want kind, better treatment.”

67 -year -old Linda Kelly is a keen gardener, who is active by cycling 60 miles a week. She also does pilates.

Breast cancer has spread to her bones and chest walls.

But he was “spectacular” results from the new drug Capivastib.

“This is a normal type of life you have and you forget that you have cancer,” he said.

“You think the medicine is working and you can be very calm – it has been given to me an additional time of about four years.”

Linda and her husband are now planning to travel. She says that the drug has given her hope.

“It thinks you about your life, and what you want to do with your life in the future – but at least you feel enough to make those plans and are sufficient to complete some of those plans.”

The drug is suitable for people with some gene mutations that affect half people with hormone receptor positive secondary breast cancer – the most common type, which increases in the presence of estrogen.

Professor Peter Johnson, the clinical director of cancer in NHS England, said that it offered “an additional option”, whose cancer has moved forward despite the previous hormone therapy – but it would not be suitable for everyone.

Charity Breast Cancer Chief Executive Officer Claire Ronnie said that she was “happy” that the drug would offer some people “expecting more precious time that matters the most”.

But he said that after the drugs were initially rejected by Nees, patients “faced unnecessary delay in accessing it”, and breast cancer drugs should be approved more quickly to those who need them.

He said, “NHS England should now conduct a early genetic test to ensure the characters that get Capivastib without further delay,” he said, Scotland should also consider the financing of treatment so that patients have access to the UK.